ICG And Sunitinib-loaded NH₂-mofs For Folate-mediated Hepatocellular Carcinoma Dual-modal Therapy

This research investigated a novel folic acid(FA)-modified zirconium core metal-organic framework(Uio-66)as a nanocarrier to deliver indocyanine green(ICG)and Sunitinib to cancer cells for combination therapy.Platinum-loaded Uio-66 nanoparticles(Pu)were synthesized via a one-pot method,followed by modification with FA on their surfaces.This afforded FPu that enabled subsequent loading of ICG and Sunitinib to achieve dual-modal cancer therapy.Drug loading/release test and singlet oxygen detection were also conducted in vitro,and the nanoparticles showed considerable drug loading efficiency for both ICG and Sunitinib,coupled with a high singlet oxygen generation rate.Specifically,the drug loading and encapsulation efficiency of Sunitinib were 2.30%and 72.67%,while those for ICG were 2.87% and 90.28%,respectively.Additionally,cytotoxicity test on Hep G2 human hepatocellular carcinoma cancer cell line revealed that the fully functional nanoparticles possess excellent biocompatibility and In vivo tumor model experiments it had also shown that nanoparticles have a strong tumor-killing effect with low toxic side effects,and that nanoparticles could also be used for in vivo/ex vivo imaging of tumors using near-infrared light.As such could be further investigated as a potential drug delivery system for effective carcinoma cancer treatment.